ライフサイエンスコーパス: first-line chemotherapy

1 er that had progressed following, or during, first-line chemotherapy.

2 tation compared with 9% in patients starting first-line chemotherapy.

3 cance of CTCs in patients with MBC receiving first-line chemotherapy.

4 al junction adenocarcinoma progressing after first-line chemotherapy.

5 ptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy.

6 ic model to predict OS in patients receiving first-line chemotherapy.

7 t is introduced immediately on completion of first-line chemotherapy.

8 who have experienced treatment failure with first-line chemotherapy.

9 plete or partial remission or no-response to first-line chemotherapy.

10 NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy.

11 dies suggested it might be an alternative to first-line chemotherapy.

12 al prognosis and few treatment options after first-line chemotherapy.

13 ts were platinum refractory and had an IR to first-line chemotherapy.

14 Of the 21,285 patients, 25.8% received first-line chemotherapy.

15 stration-resistant prostate cancer receiving first-line chemotherapy.

16 all-cell lung cancer (SCLC) after failure of first-line chemotherapy.

17 ecision compared with women who were offered first-line chemotherapy.

18 1 patients after a complete response (CR) to first-line chemotherapy.

19 d with 2.3 months (range, 0.2 to 28.1) after first-line chemotherapy.

20 At first line chemotherapy, 44 patients received one day GE

21 an cancer (EOC) after surgical resection and first-line chemotherapy, about 60% of patients will re-d

22 ugs that induce DNA damage are commonly used first-line chemotherapy agents for testicular, bladder,

23 enteen interviews included 70 in relation to first-line chemotherapy and 47 in relation to second-lin

24 All patients were refractory to first-line chemotherapy and 88% had received prior radio

25 ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuatio

26 In this study, we evaluate benefit from first-line chemotherapy and characterize imaging respons

27 roven APC were randomly assigned to ambulant first-line chemotherapy and prophylactic use of enoxapar

28 we further assess TG4010 in combination with first-line chemotherapy and use of the TrPAL biomarker i

29 ge IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progre

30 al therapy and consolidation treatment after first-line chemotherapy are as yet undefined.

31 dvanced ovarian cancer, rates of response to first-line chemotherapy are high but most patients have

32 n patients treated with EGFR inhibitors plus first-line chemotherapy are unknown.

33 of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Cent

34 Patients obtaining a CR after first-line chemotherapy can be safely observed without P

35 trate, partly because some patients who fail first-line chemotherapy can be salvaged in second remiss

36 iable salvage treatment for patients in whom first-line chemotherapy cannot control the disease.

37 EOC have a poorer response to platinum-based first-line chemotherapy compared with patients with othe

38 ith doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer

39 tments and biomarkers: (1) After a period of first-line chemotherapy, do targeted novel therapies pro

40 Doxorubicin, a first-line chemotherapy drug, often causes myelosuppress

41 persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternate

42 First-line chemotherapy fails in more than 20% of patien

43 vival compared with the standard sequence of first-line chemotherapy followed by erlotinib.

44 Cisplatin is a first line chemotherapy for most types of cancer.

45 Cisplatin-based treatment is the first line chemotherapy for several cancers including ov

46 with historical outcomes achieved with other first-line chemotherapies for advanced STS.

47 dult women who had progressive disease after first-line chemotherapy for advanced or metastatic endom

48 Patients age >/= 70 years receiving first-line chemotherapy for cancer were prospectively co

49 cal response rates to docetaxel, the current first-line chemotherapy for castration-resistant disease

50 ional advantage to using EP instead of EC as first-line chemotherapy for MBC in taxane-naive patients

51 imastat does not prolong PFS when used after first-line chemotherapy for metastatic breast cancer.

52 teoclasts, and has synergy with docetaxel, a first-line chemotherapy for metastatic castration-resist

53 dies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lu

54 First-line chemotherapy for patients with cisplatin-inel

55 Cisplatin is the first-line chemotherapy for the treatment of several can

56 than 70 years of age who were scheduled for first-line chemotherapy for various types of cancer were

57 e combination of paclitaxel and cisplatin as first-line chemotherapy for women with advanced breast c

58 who have disease progression during or after first-line chemotherapy have limited treatment options.

59 assessed in combination with platinum-based first-line chemotherapy in a large phase 3 trial.

60 ernational, prospective, randomized trial of first-line chemotherapy in advanced ovarian cancer (doce

61 trial is comparable to results observed with first-line chemotherapy in chemotherapy-naive patients.

62 sibility study of cisplatin and docetaxel as first-line chemotherapy in International Federation of G

63 rastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that

64 vival when used in combination with standard first-line chemotherapy in patients with advanced NSCLC

65 The addition of SIRT to FOLFOX-based first-line chemotherapy in patients with liver-dominant

66 ination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread meta

67 astration-resistant prostate cancer starting first-line chemotherapy in the IMMC38 trial.

68 We conclude that first-line chemotherapy including rituximab is associate

69 stablish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal

70 l cancer that progressed, were intolerant to first-line chemotherapy, or had disease recurrence withi

71 ts with stage IV colorectal cancer receiving first-line chemotherapy, particularly in black and femal

72 ease progression on or within 4 months after first-line chemotherapy (platinum plus fluoropyrimidine

73 fied according to their previous response to first-line chemotherapy (primary refractory v primary se

74 ry tumor site and prior complete response to first-line chemotherapy program).

75 site and a prior complete response (CR) to a first-line chemotherapy program, which had been identifi

76 LFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorecta

77 Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanc

78 maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for adv

79 stration of a lower intensity version of the first-line chemotherapy regimen).

80 scan result, number of metastatic sites, and first-line chemotherapy regimen.

81 gemcitabine plus docetaxel is an appropriate first-line chemotherapy regimen.

82 The addition of cetuximab to first-line chemotherapy seems to benefit patients with K

83 ould be an alternative or even the preferred first-line chemotherapy strategy for patients with metas

84 ge IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance

85 tients with liver-only disease included in a first-line chemotherapy study, the NORDIC VII study (n =

86 of BAX achieved a complete response (CR) to first-line chemotherapy that contained paclitaxel plus a

87 tients who had previously achieved a CR to a first-line chemotherapy trial, 17 were identified as hav

88 erapy, and is similar to the results of many first-line chemotherapy trials in this setting.

89 led with patients with distant metastases in first-line chemotherapy trials not suited to define the

90 the decision-making process (33%, n = 23 at first-line chemotherapy v 43%, n = 20 at second-line che

91 atient interviews; 19%, n = 13 being offered first-line chemotherapy v 43%, n = 20 being offered seco

92 odel for OS in patients with mCRPC receiving first-line chemotherapy was developed and validated on a

93 e cancer, age > or = 65 years, and receiving first-line chemotherapy were included.

94 an advanced cancer diagnosis and failure of first-line chemotherapy were interviewed at baseline reg

95 e IIIB-IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 throu

96 treatment cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients wit

97 d germ cell tumors (GCTs) who relapsed after first-line chemotherapy with cisplatin and etoposide wit

98 e in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated w

99 studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin

100 of HER2-positive gastric cancer treated with first-line chemotherapy with trastuzumab.

101 cond-line treatment in patients who received first-line chemotherapy, without prior immune checkpoint

102 her changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcom